3.1 Celtis sinensis leaf extract (CLE) protects mice from allergic contact dermatitis
Celtis sinensis is employed as a folk medicine for treating inflammation, skin infections and other diseases24. To study the possibility of using Celtis sinensis to treat inflammation in GA-induced allergic contact dermatitis, a mouse model of GA-induced hypersensitive contact dermatitis was established. We stimulated the popliteal lymph nodes and the left ear of ICR mice by GA (Fig. 1A). Mice challenged by GA displayed definite inflammation, as indicated by splenomegaly and ear swelling, compared with the vehicle group.
Celtis sinensis leaf extract (investigational ingredient, CLE) and dexamethasone (positive control drug, Dex) were used to treat the degree of ear swelling. Notably, mice that received CLE exhibited significantly reduced susceptibility to GA-induced allergic contact dermatitis, as shown by the milder splenomegaly and ear swelling compared with the model group (Fig. 1B and C). Indeed, CLE did not decrease the body weight of mice, but it appeared in mice that received dexamethasone (Fig. 1D). Histopathologically, mice that received CLE displayed significantly alleviated leukocyte infiltration, epidermal anabrosis and affection damage compared with the vehicle group (Fig. 1E and F). Collectively, intragastric instillation of CLE confers protection from GA-induced allergic contact dermatitis in ICR mice.
3.2 Isovitexin, the main flavonoid in the leaves of Celtis sinensis, ameliorates GA-induced allergic contact dermatitis in mice
Since isovitexin (Fig. 2A) is the predominant flavone of Celtis sinensis25, we further examined the possible role of isovitexin in dermal inflammation. Mice that received isovitexin exhibited ameliorative ear swelling and splenomegaly compared with the model group (Fig. 2B and C). Meanwhile, consistent with the CLE experiments, isovitexin did not show body weight loss, suggesting that compared with dexamethasone, isovitexin displayed significant anti-inflammatory function without serious side effects (Fig. 2D). Histopathologically, mice that received isovitexin displayed directly reduced leukocyte chemotaxis and ameliorated proinflammatory cytokine release (Fig. 2E and F). Therefore, isovitexin, a natural flavone, exerts immunosuppressive effects in GA-induced allergic contact dermatitis
3.3 Isovitexin inhibits T cell-mediated inflammation in mice with GA-induced allergic contact dermatitis
Stimulation with GA also exacerbated the release of inflammatory cytokines (TNF-α, IFN-γ, IL-2, and IL-17A) in serum. The upregulation of these T cell-specific cytokines indicates that GA-induced allergic contact dermatitis mainly triggers inflammatory activation of T cells rather than macrophage-mediated innate inflammation. The anti-inflammatory effects of isovitexin were presumably attributed to a decrease in T cell-specific cytokines in serum (Fig. 3A). We then evaluated the mRNA level of T cell-associated cytokines in popliteal lymph nodes. Compared with inflamed dermatitis mice, the contents of tnf-α, ifn-γ, il-2, and il-17a were significantly lower in mice that received isovitexin (Fig. 3B and C). Moreover, we observed that proapoptotic proteins (cleaved caspase-3 and cleaved PARP) were activated and that proliferation proteins (phosphor-AKT and phospho-ERK1/2) were inhibited in isovitexin-treated T cells from allergic mice (Fig. 3D and E). Taken together, these data clearly demonstrate that isovitexin may inhibit T cell-mediated inflammatory responses in dermatitis.
3.4 Isovitexin inhibits the proliferation and promotes apoptosis of Con A-activated T cells in vitro
The above findings prompted us to suppose that isovitexin diminished T cell proinflammatory activities in response to GA stimulation. Furthermore, we used Con A-activated T cells to explore the mechanisms underlying the antagonizing effects of isovitexin on metabolic disorders. Con A is a plant lectin that induces the mitogenic activity of T lymphocytes and increases the production of inflammatory cytokines such as IL-2, TNF-α and IFN-γ26. The MTT assay was used to assess cell viability. As shown in Fig. 4B, Con A (5 μg/ml) strongly promoted T cell proliferation. In addition, cell culture with the addition of 0-100 μM isovitexin was not toxic to naïve T cells, but it inhibited the proliferation of Con A-activated T cells (Fig. 4A and B). On the other hand, isovitexin triggered apoptosis of Con A-activated T cells, as analyzed by the Annexin V/PI staining assay (Fig. 4C). The percentages of early apoptotic T cells significantly increased with different doses of isovitexin after 24 h of incubation. To define the pathway of apoptosis, western blotting was used to analyze the cleavage of poly (ADP-ribose) polymerase (PARP) and caspase. Strong cleavage of PARP together with activation of caspase-3 and -8 were observed in the Con A-activated T cells treated with isovitexin, which is consistent with the results of animal experiments (Fig. 4D and E). These observations indicate that isovitexin inhibits the proliferation of Con A-activated T cells by promoting apoptosis.
3.5 Isovitexin inhibits the production of proinflammatory cytokines in Con A-activated T cells
Numerous apoptotic cells have been shown to inhibit proinflammatory cytokine production, preventing chronic inflammation27. For this claim, we examined whether isovitexin is linked with the production of proinflammatory cytokines, including TNF-α, IFN-γ, IL-2 and IL-17A. ELISA was performed to measure the release of cytokines in the culture supernatant, and RT-PCR was carried out to measure the expression of these cytokines from Con A–activated T cells (Fig. 5A, B and C). Interestingly, at a concentration of 100 μM, isovitexin significantly reduced the levels of proinflammatory cytokines (TNF-α, IFN-γ, IL-2 and IL-17A) at both the mRNA and protein levels.
3.6 The MAPK and STAT signaling pathways are regulated by isovitexin in Con A-activated T cells
The MAPK and STAT signaling pathways govern the expression of most proinflammatory genes28,29. To understand how isovitexin modulates inflammatory responses in T cells, we examined the relationship between isovitexin and these pathways. Mechanistically, T cells treated with 100 μM isovitexin exhibited markedly reduced phosphorylation of proteins such as P38, JNK, and ERK1/2 in Con A-induced T cells, which are the central kinases in the MAPK signaling pathway that cause inflammation. On the other hand, isovitexin dose-dependently decreased the level of IκB phosphorylation. The kinase is activated by a highly diverse group of extracellular signals, including inflammatory cytokines, growth factors, and chemokines. Unexpectedly, isovitexin did not affect the expression of p65 in whole cell lysate, and whether p65 is in the core needs to be further proven. Western blotting was also used to explore whether isovitexin decreased the phosphorylation of STAT3, STAT6, and SHP2, which play important roles in the proliferation and differentiation of T cells. Thus, isovitexin serves as a negative regulator of the MAPK and STAT signaling pathways (Fig. 6A and B).
3.7 Molecular docking analysis of the interaction between isovitexin and SHP2 protein
Next, we sought to determine the molecular mechanisms by which isovitexin modulates the MAPK and STAT signaling pathways in Con A-activated T cells. We first tested whether isovitexin might interact with SHP2. The interaction between the SHP2 protein and isovitexin was demonstrated by molecular docking analysis. As shown in the figure, there is a certain intensity of interaction between SHP2 and isovitexin, and the best induced-fit docking score is -5.414 kcal/mol, where isovitexin can insert into the active domain of SH2 kinase and interact by hydrogen bonding and π–π interactions (Fig. 6C). The docking results suggest that there is obvious π-π conjugation between TYR279, the B ring and the C ring of isovitexin. There may be two hydrogen bond interactions between SHP2 and isovitexin: one formed between the ASN281 residue and 4'-OH on the C ring of isovitexin, and the other formed between GLN and the carbonyl group on the B ring of isovitexin. Indeed, the A ring of isovitexin forms seven kinds of hydrogen bonds with SHP2 with ASP425, LYS366, AGR465, TRP423 and GLY427, which confer stability to the docking conformation (Fig. 6D).
3.8 The effects of isovitexin on Con A-activated T cells can be reversed by the SHP2-specific inhibitor SHP099
SHP099, a selective SHP2 inhibitor, binds to protein tyrosine phosphatase domains, inhibiting SHP2 activity through an allosteric mechanism30. We investigated whether isovitexin suppressed the release of cytokines by regulating SHP2 in Con A-activated T cells, and the effects were examined in SHP099-treated cells. The results showed that the inhibitory effects of isovitexin on T cell proliferation and proinflammatory cytokine production were partially reversed by SHP099 (Fig. 7A and B). Moreover, the regulation of the expression of p-STAT3 and p-STAT6 was partially reversed by SHP099 as well in T cells incubated with isovitexin (Fig. 7C and D). In summary, our study proved that isovitexin restrains p-SHP2 and controls dermatitis inflammation (Fig. 8).